FVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction
|
|
- Laureen Bradford
- 6 years ago
- Views:
Transcription
1 Original Research PSYCHOLOGICAL TESTING FVC to Slow Inspiratory Vital Capacity Ratio* A Potential Marker for Small Airways Obstruction Judith Cohen, MD; Dirkje S. Postma, MD, PhD; Karin Vink-Klooster; Wim van der Bij, MD, PhD; Erik Verschuuren, MD, PhD; Nick H. T. ten Hacken, MD, PhD; Gerard H. Koëter, MD, PhD; and W. Rob Douma, MD, PhD Background: The ratio of FVC to slow inspiratory vital capacity (SVC) has been reported to reflect small airways obstruction, but its validity as such is still unclear. The aim of this study was to assess the applicability of the FVC/SVC ratio as a marker of small airways function in patients with bronchiolitis obliterans syndrome (BOS) after lung transplantation (LTX), which is a disorder in which predominantly small airways obstruction causes progressive airflow limitation. Methods: The FVC/SVC ratio was analyzed both cross-sectionally and longitudinally in 39 patients (26 men) with BOS after bilateral LTX (median age, 47 years; interquartile range [IQR], 35 to 54 years), and 36 bilateral lung transplant recipients without BOS (14 men; median age, 46 years; IQR, 41 to 53 years). Results: The FVC/SVC ratio decreased significantly during follow-up in patients with BOS stages 1 and 2, by 2.2% and 4.4%, respectively, from baseline (p < 0.001). This decrease was not significantly associated with the decrease in FEV 1. The FVC/SVC ratio increased, though not significantly, in the group in which BOS did not develop by 1.1%, which is a significant difference from the average fall of 4.4% in the group in which BOS developed. Conclusions: Significant, yet small decreases in FVC/SVC ratio occur in patients in whom BOS develops, independent from changes in FEV 1. At a group level, FVC/SVC ratio is able to detect small airways changes. These results merit prospective studies to determine the sensitivity of FVC/SVC ratio to quantifying small airways dysfunction at an individual level and in other airway diseases. (CHEST 2007; 132: ) Key words: FVC; inspiratory vital capacity; small airways obstruction; spirometry Abbreviations: BOS bronchiolitis obliterans syndrome; FEF 25 75% forced expiratory flow between 25% and 75% of FVC; IQR interquartile range; LTX lung transplantation; SVC slow inspiratory vital capacity Over the last decade, there has been a renewed and increasing interest in the role of small airways in pulmonary disease. The so-called small airways (ie, those 2 mm in internal diameter) are not only affected in classic small airways diseases such as bronchiolitis obliterans, but are also important locations of inflammation in obstructive airways diseases such as asthma and COPD. 1 This understanding has led to the search for valid parameters that can identify, quantify, and evaluate small airways pathology. Small airways are a relatively inaccessible and therefore difficult area to investigate. Transbronchial biopsies and CT scans are being used as tools to assess small airways pathology. However, they are relatively invasive, burdening, and costly procedures; thus, noninvasive methods that can easily be repeated for follow-up reflecting small airways function are to be preferred. Pulmonary function testing via spirometry is such a method. FVC and slow inspiratory vital capacity (SVC) are parameters that may contain important information on the functioning of small airways. Factors that may limit the magnitude of FVC and SVC, as measured in an individual, are alveolar collapse, airway closure and elastic recoil of the chest wall, which diminishes with aging. 2 In asthma pa Original Research
2 tients, it has been described that the difference between FVC and SVC is greater than in healthy control subjects and can be used as an index of small airways collapse. This difference increases when more airway obstruction is present and the disease is more severe. 2,3 Not only the difference between FVC and SVC but also the ratio between the two parameters has been applied in research as an indicator of small airways collapse and air trapping. 4,5 However, FVC/SVC ratio has not been fully validated so far. The few studies that have described the use of FVC/SVC ratio focus on obstructive airways diseases; thus, it is uncertain to what extent the small airways are affected, since larger airways have been demonstrated to contribute to airway obstruction as well. To further evaluate the applicability of FVC/SVC ratio as a marker of small airways function and to minimize the contribution of large airway narrowing, FVC/SVC ratio was evaluated in patients with bronchiolitis obliterans syndrome (BOS), which is a type of chronic allograft rejection occurring after lung transplantation (LTX) in which small airways become progressively obliterated leading to airway obstruction. 6 We hypothesized that FVC/SVC ratio, if it is a valid small airways parameter, should detect small airways changes in patients with BOS and tested this in a well-defined patient group after they had undergone LTX. Subjects Materials and Methods This particular study involves the use of anonymized data from human subjects and explicitly does not involve the use of human subjects. According to Dutch legislation, data analyses like the current study do not require review by local or central ethics committees. All patients (n 184) who underwent bilateral LTX between 1992 and 2002 at the University Medical Center Groningen (Groningen, the Netherlands) and in whom BOS developed at least up to stage 2 were included in the analysis. Patients who *From the Departments of Pulmonology (Drs. Cohen, Postma, ten Hacken, Koëter, and Douma), Pulmonary Function (Ms. Vink-Klooster), and Lung Transplantation (Drs. van der Bij and Verschuuren), University Medical Center Groningen, University of Groningen, Groningen, the Netherlands. The authors have reported to the ACCP that no significant conflicts of interest exist with any companies/organizations whose products or services may be discussed in this article. Manuscript received June 14, 2006; revision accepted June 8, Reproduction of this article is prohibited without written permission from the American College of Chest Physicians ( org/misc/reprints.shtml). Correspondence to: W. Rob Douma, MD, PhD, Secretariaat Longziekten UMCG, PO Box 30001, 9700 RB Groningen, the Netherlands; w.r.douma@int.umcg.nl DOI: /chest LTX recipients WITH BOS Lung function data: 1. Baseline (median 188 days after transplantation) 2. BOS stage 1 (median 371 days after baseline) (also: Time point A) 3. BOS stage 2 (median 578 days after baseline) (also: Time point B) 184 bilateral LTX recipients LTX recipients with complete lung function data (FVC, SVC, FEF and FEV 1 ) 36 LTX recipients WITHOUT BOS Lung function data: 1. Baseline (median 226 days after transplantation) 2. Time point A (median 362 days after baseline) 3. Time point B (median 599 days after baseline) Figure 1. Selection of subjects and lung function data. underwent unilateral LTX were not included because of the possible interference of the remaining autologous lung with the measured lung function parameters. Thirty-nine patients were suitable for analysis and had a complete data set with regard to follow-up of FEV 1, forced expiratory flow between 25% and 75% of FVC (FEF 25 75% ), FVC, and SVC (median follow-up time from LTX to BOS stage 2, 912 days; interquartile range [IQR], 505 to 2,181 days). The control group consisted of 36 patients who had undergone bilateral LTX but in whom BOS of any stage did not develop (Fig 1). The lung function of these subjects was matched in time intervals with the median number of days in the BOS group (median follow-up time from LTX, 824 days; IQR, 809 to 842 days). Methods A routine clinical and spirometric follow-up took place in all post-ltx patients. Routine pulmonary function tests were performed two to three times weekly during hospitalization and weekly during the first 2 to 3 months after transplantation in the outpatient setting, and visits were tapered to a minimum frequency of once every 3 months. 7 Each stable post-ltx patient was classified as having BOS stage 0, based on their baseline FEV 1. The term baseline in this article represents the first measurement after LTX with the patient in the stable phase. Progressive BOS stages were defined based on an increasing decline in FEV 1 and or a decline in FEF 25 75% (Table 1) according to International Society for Heart and Lung Transplantation recommendations. 8 In the BOS group, the median number of days from the LTX date to the baseline phase and from the baseline phase to reaching BOS stages 1 and 2 were BOS Stage Table 1 Classifications of BOS* Decline in FEV 1 From Baseline Decline in FEF 25 75% From Baseline 0 10% and 25% 0-p (at risk) 10 19% and/or 25% % NA % NA 3 50% NA *Baseline values are determined in each stable post-lung transplant recipient according to International Society for Heart and Lung Transplantation recommendations. 8 NA not applicable. CHEST / 132 / 4/ OCTOBER,
3 calculated. In the control group, which consisted of LTX recipients in whom BOS did not develop, pulmonary function measurements were selected to match time intervals similar to those in the BOS group reaching the consecutive baseline and BOS stages. These equivalent time intervals were named time interval A (an equivalent time interval from baseline to BOS stage 1 in the group with BOS) and time interval B (an equivalent time interval from baseline to BOS stage 2 in the group with BOS). Spirometric values were assessed with a pneumotachograph that was calibrated daily (Masterscreen Pneumo or Masterscreen IOS; Jaeger; Würzburg, Germany) and were obtained according to European Respiratory Society recommendations. 9 Subjects did not use bronchodilators if applicable within 12 h before the measurements. Statistical Analysis Pulmonary function data and baseline characteristics were investigated. Patients with BOS stage 0-p (indicating BOS at risk ) and BOS stage 3 were not included in the analysis. Descriptive statistics were applied to baseline characteristics. Declines in FEV 1, FVC, SVC, and FVC/SVC ratio from baseline were statistically tested for significant difference by means of a Wilcoxon signed rank test in both the BOS group and the control group. Differences in variables between groups with and without BOS were statistically tested with Mann-Whitney U tests. Correlations of the change in FVC/ SVC ratio with the change in FEV 1 and FEF 25 75% were calculated with Spearman nonparametric ranking tests. Since the variables used had a skewed distribution in this population, only nonparametric tests were used. To determine independent prognostic factors for baseline FVC/SVC ratio, a multivariate regression analysis in a stepwise algorithm was used (SPSS, version for Windows; SPSS Inc; Chicago, IL). Results Baseline FVC/SVC Ratio Table 2 presents the baseline characteristics of 39 patients in whom BOS up to stage 2 developed and of 36 patients in whom BOS did not develop after bilateral LTX. There were significantly more men in the group with BOS than in the group without BOS (p 0.017) [Table 2]. There was no significant difference between the baseline FVC/SVC ratio in both groups, and there was also no significant gender difference in the baseline FVC/SVC ratio within each group. The diagnoses prior to LTX were comparable in both groups. A multivariate regression model with baseline FVC/SVC ratio as the dependent variable, and age at transplantation, gender, and height of both the donor and the recipient entered as covariates revealed no factors significantly influencing the baseline FVC/SVC ratio. Decrease in FVC/SVC Ratio In the BOS group, FVC/SVC ratio significantly decreased from baseline in patients with stage 1 and 2 BOS (Table 3). In the group of patients in whom BOS did not develop, FVC/SVC ratio did not decrease significantly after median periods of 362 days (time point A) and 599 days (time point B) from baseline but even increased by 1.2% and 1.1%, respectively, though not significantly. These time intervals correspond with the median time intervals from baseline to stage 1 and 2 BOS in the BOS group. The decline in FVC/SVC ratio from baseline was significantly larger in the BOS group than in the group without BOS (ie, a decrease of 2.2% vs an increase of 1.2%, respectively [p 0.001], and a decrease of 4.4% vs an increase of 1.1% [p 0.001], respectively) [Table 3, Fig 2]. The FVC/SVC ratios at time point A and time point B were significantly lower in the group with BOS than in the group without BOS (p 0.001) [Fig 2]. Within the BOS group, the median FVC/SVC ratio was significantly lower in patients with stage 2 BOS than in those with stage 1 BOS (96% [IQR, 92 to 100] vs 98% [IQR, 94 to 100], respectively; p 0.039). In the group without BOS, the FVC/SVC ratio was not significantly different at time point A and B (102% [IQR, 100 to 104] vs 102% [IQR, 99 to 105], respectively). Although there were significantly more men in the BOS group than in the group without BOS (p 0.017), the decline in FVC/SVC ratio per time interval was not significantly different in men and women (p 0.05) who had stage 1 and 2 BOS. The Table 2 Baseline Characteristics* Characteristics Patients With BOS (n 39) Patients Without BOS (n 36) p Value Gender, No Male Female Age at lung transplantation, yr 47.5 ( ) 46.2 ( ) Age of donor, yr 38.0 ( ) 37.0 ( ) Height of transplant recipient, cm 174 ( ) 170 ( ) Height of transplant donor, cm 180 ( ) 175 ( ) FEV 1 at baseline, L 3.17 ( ) 2.87 ( ) FVC/SVC ratio at baseline, % ( ) ( ) *Values are given as the median (IQR), unless otherwise indicated. Statistical differences between the group with BOS and the group without BOS were assessed with Mann-Whitney U tests Original Research
4 Table 3 Lung Function Parameters in Patients With and Without BOS* Time Interval, % Change From Baseline Variables Baseline (Absolute Values) A B FEV 1,L Group with BOS 3.2 ( ) 23.7 ( 22.0 to 26.2) 39.0 ( 36.4 to 42.1) Group without BOS 2.9 ( ) 3.2 ( 5.5 to 8.9) NS 3.0 ( 2.9 to 7.6) FEF 25 75%, L/s Group with BOS 3.3 ( ) 52.2 ( 44.6 to 61.8) 72.4 ( 63.6 to 77.3) Group without BOS 3.6 ( ) 5.5 ( 13.5 to 8.6) NS 7.6 ( 28.3 to 1.9) FVC, L Group with BOS 3.8 ( ) 9.2 ( 1.0 to 15.8) 18.3 ( 8.5 to 25.1) Group without BOS 3.2 ( ) 5.7 ( 0.1 to 9.4) 7.7 (2.4 to 12.7) SVC, L Group with BOS 3.7 ( ) 4.3 (3.0 to 13.5) 14.3 ( 3.7 to 21.5) Group without BOS 3.1 ( ) 5.4 ( 1.1 to 8.8) 5.4 (2.9 to 11.6) FVC/SVC ratio, % Group with BOS ( ) 2.2 (0.0 to 6.5) 4.4 ( 1.2 to 7.5) Group without BOS ( ) 1.2 ( 1.6 to 3.0) NS 1.1 ( 1.7 to 2.5) NS *Values are given as the median (IQR). Time interval A corresponds with the time from baseline to BOS stage 1 (median time, 371 days after baseline) in the BOS group and for the group without BOS with an equivalent time interval (median time, 362 days after baseline). Time interval B corresponds with the time from baseline to BOS stage 2 (median time, 578 days after baseline) in the BOS group and for the group without BOS with an equivalent time interval (median time, 599 days after baseline). NS not significant. p p p minimum and maximum values of the FVC/SVC ratio at all time points were 84% and 114%, respectively, in the total study group. In patients with stages 1 and 2 BOS, the decline in FVC/SVC ratio from baseline did not significantly correlate with the decline in FEV 1 from baseline ( [p 0.637] vs [p 0.672], respectively) or with FVC/SVC (%) * * 120 BOS group Group without BOS 110 * p< p = * * Baseline 'A' 'B' Figure 2. FVC/SVC ratio at baseline, time point A, and time point B. Time interval A corresponds with the time from baseline to stage 1 BOS (median time, 371 days after baseline) in the BOS group and for the group without BOS with an equivalent time interval (median time, 362 days after baseline). Time interval B corresponds with the time from baseline to stage 2 BOS (median time, 578 days after baseline) in the BOS group and for the group without BOS with an equivalent time interval (median time, 599 days after baseline). FVC/SVC ratio is significantly lower in the BOS group at time points A and B (p [Mann-Whitney U test]) than in the group without BOS. Within the BOS group, the FVC/SVC ratio at time points A and B is significantly lower than baseline (p [Wilcoxon signed rank test]). Within the BOS group, FVC/SVC ratio at time point B is significantly lower than FVC/SVC ratio at time point A (p [Wilcoxon signed rank test]). the decline in FEF 25 75% from baseline ( [p 0.818] vs [p 0.510], respectively). Discussion Our data show that FVC/SVC ratio decreases significantly with progressing BOS stages, which occurs independently from changes in FEV 1. These together may indicate that at a group level the FVC/SVC ratio assesses small airways changes. This study is one of the first to investigate the properties of the FVC/SVC ratio and its ability to reflect small airways obstruction. To our knowledge, Wenzel and colleagues 4 were the first to mention the use of FVC/SVC ratio in a biopsy study in patients with severe asthma. They demonstrated that a smaller FVC/SVC ratio was significantly associated with the presence of eosinophils in lung tissue. 4 In this population with severe asthma, the FVC/SVC ratio ranged between 71% and 100%, which is a different range than we demonstrated in our LTX population (range, 84 to 114%). Based on just two studies, it is difficult to pass judgement on this difference in ratios. Asthma and BOS are dissimilar airway diseases, which may partially account for the difference in FVC/SVC ratios. It seems likely that the contribution of larger airways to airflow limitation is more pronounced in patients with severe asthma than in those with stage 1 and 2 BOS, in which predominantly smaller airways are affected. A CHEST / 132 / 4/ OCTOBER,
5 second explanation for the difference in FVC/SVC ratios may be that different types of inflammation exist in patients with severe asthma and BOS after LTX. In the study by Wenzel et al, 4 patients with severe asthma but without increased eosinophil numbers in lung tissue demonstrated FVC/SVC ratios that were similar to those of our BOS population (ie, 97%; range, 89 to 100%). This may indicate that eosinophilic inflammation in particular determines the level of FVC/SVC ratio more than the presence of small airway obstruction. A third explanation may be that stretch receptors play a role in the magnitude of the FVC/SVC ratio. In humans, a deep inspiration has been shown to stimulate stretch receptors in the lung, which may lead to bronchoconstriction 10 and thus to a lower FVC/SVC ratio. In LTX recipients, there is a loss of pulmonary stretch receptors, 11 which may explain why the FVC/SVC ratio is less attenuated in our patients with BOS after LTX than in the patients with severe asthma. 4 In patients with stage 1 and 2 BOS, the decline in FVC/SVC ratio was not associated with the decline in FEV 1. This may indicate that the FVC/SVC ratio reflects the functioning of different airway divisions than FEV 1. The observed decline in FVC/SVC ratio per BOS stage, which is independent of the decline in FEV 1, in combination with the absence of a decline in FVC/SVC ratio in the control group supports the hypothesis that the FVC/SVC ratio may serve as a parameter for detecting small airways changes. Nevertheless, the reduction in FVC/SVC ratio with progressive disease is fairly small and may prove to be too small to be of value in the monitoring of small airway disease in all individual patients. Whether FVC/SVC ratio is a sensitive parameter that will aid in elucidating early or pending stages of BOS on an individual level should therefore be assessed in future studies. In this retrospective study, patients with stages 0-p and 3 BOS were excluded from the analyses. BOS stage 0-p, indicating BOS at risk, was not included in the analysis because BOS does not actually develop in all patients classified as having BOS 0-p. Hence, there may be minimal small airways pathology in this group. In patients with stage 3 BOS, larger airways as well as small airways may be severely affected, and infections frequently play a role. For these reasons, we considered that BOS stages 0-p and 3 were not typical states for small airways disease, and they were thus unsuitable stages for evaluating the characteristics of the FVC/SVC ratio. Nevertheless, it is possible that some patients with BOS who were evaluated in this study have some extent of larger airway abnormalities as well. We evaluated the FVC/SVC ratio as an index of small airway obstruction in patients with BOS, which is a disease that is defined by especially small airway disease. It may be questioned whether the observed decline in FVC/SVC ratio is due to small airway obstruction or whether it is merely a logical result of the decline in FEV 1 since both parameters are extracted from the same flow volume maneuver. In that case, FVC/SVC ratio would only be a different way to express airway obstruction in general, rather than reflecting specific obstruction in the small airways. However, our results do not support this notion. There was no significant or clinically relevant correlation between the decline in FEV 1 and the decline in FVC/SVC ratio, indicating that the observed and significant decrease of FVC/SVC ratio in BOS is independent of the decrease in FEV 1. Some may state that a limitation of our study is that we did not correlate the decline in FVC/SVC ratio with changes in parameters other than lung function, such as radiologic or pathologic changes that may be observed in patients with BOS. However, current International Society for Heart and Lung Transplantation guidelines 8 state that the diagnosis of BOS is based purely on a decline in FEV 1. Therefore, irrespective of radiologic or pathologic data, the diagnosis of BOS would still be valid only if a decline in FEV 1 was observed. This would therefore not change the selection of the groups in this study and would also not change the outcomes. As mentioned before, in the absence of a valid small airway obstruction parameter BOS is still classified by the use of FEV 1. In the earlier developmental stages of BOS, small airways are relatively the most affected by disease, which is why the use of FEF 25 75% has been implemented in the classification of BOS stage 0-p, indicating patients who are at risk for the development of BOS. It is unclear whether FEF 25 75% is a reliable measure in classifying BOS stage 0-p since the relationship between FEF 25 75% and histologic changes is unknown. 12 Possibly, other small airway parameters such as FVC/SVC ratio, if proven feasible for detecting small airway pathology in the individual patient, may come of use in classifying the early stages of BOS. In conclusion, we have for the first time investigated the applicability of the FVC/SVC ratio as a parameter for small airway obstruction in a classic small airway disease. FVC/SVC ratio can demonstrate small airway dysfunction on a group level, when comparing patients with and without BOS at a matched time after bilateral LTX. Since the observed changes in FVC/SVC ratio with progressive small airway obstruction were fairly small, further prospective studies are needed to assess whether FVC/SVC ratio is an early signal of a pending BOS syndrome at an individual level. Future studies may also assess whether FVC/SVC ratio could be of value 1202 Original Research
6 as a sensitive parameter of small airway involvement in other diseases, such as asthma and COPD. References 1 Shaw RJ, Djukanovic R, Tashkin DP, et al. The role of small airways in lung disease. Respir Med 2002; 96: Chhabra SK. Forced vital capacity, slow vital capacity, or inspiratory vital capacity: which is the best measure of vital capacity? J Asthma 1998; 35: Chan ED, Irvin CG. The detection of collapsible airways contributing to airflow limitation. Chest 1995; 107: Wenzel SE, Schwartz LB, Langmack EL, et al. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics. Am J Respir Crit Care Med 1999; 160: Postma D. Perspectives for future asthma treatment: the role of small airways. 2004; Estenne M, Hertz MI. Bronchiolitis obliterans after human lung transplantation. Am J Respir Crit Care Med 2002; 166: Ouwens JP, van der Mark TW, Koeter GH, et al. Bronchiolar airflow impairment after lung transplantation: an early and common manifestation. J Heart Lung Transplant 2002; 21: Estenne M, Maurer JR, Boehler A, et al. Bronchiolitis obliterans syndrome 2001: an update of the diagnostic criteria. J Heart Lung Transplant 2002; 21: Quanjer PH, Tammeling GJ, Cotes JE, et al. Lung volumes and forced ventilatory flows: report Working Party Standardization of Lung Function Tests, European Community for Steel and Coal; Official Statement of the European Respiratory Society. Eur Respir J Suppl 1993; 16: Meessen NE, van der Grinten CP, Luijendijk SC, et al. Breathing pattern during bronchial challenge in humans. Eur Respir J 1997; 10: Flume PA, Eldridge FL, Edwards LJ, et al. Relief of the air hunger of breathholding: a role for pulmonary stretch receptors. Respir Physiol 1996; 103: Sutherland ER, Martin RJ, Bowler RP, et al. Physiologic correlates of distal lung inflammation in asthma. J Allergy Clin Immunol 2004; 113: CHEST / 132 / 4/ OCTOBER,
Outline FEF Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications?
Reduced FEF25-75 in asthma. What does it mean and what are the clinical implications? Fernando Holguin MD MPH Director, Asthma Clinical & Research Program Center for lungs and Breathing University of Colorado
More informationCitation for published version (APA): Ouwens, J. P. (2002). The Groningen lung transplant program: 10 years of experience Groningen: s.n.
University of Groningen The Groningen lung transplant program Ouwens, Jan Paul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationCitation for published version (APA): Ouwens, J. P. (2002). The Groningen lung transplant program: 10 years of experience Groningen: s.n.
University of Groningen The Groningen lung transplant program Ouwens, Jan Paul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationDifference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 4 Number 2 Difference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction
More informationSmall Airways Disease. Respiratory Function In Small Airways And Asthma. Pathophysiologic Changes in the Small Airways of Asthma Patients
Small Airways Disease Respiratory Function In Small Airways And Relevant Questions On Small Airway Involvement In How can small airway disease be defined? What is the link between small airway abnormalities
More informationIncreased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients
Yuan et al. BMC Pulmonary Medicine 2014, 14:16 RESEARCH ARTICLE Open Access Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients Wei
More informationRelationship of Small Airway Chymase-Positive Mast Cells and Lung Function in Severe. Asthma
Relationship of Small Airway Chymase-Positive Mast Cells and Lung Function in Severe Asthma Silvana Balzar, M.D., Hong Wei Chu, M.D., Matthew Strand, Ph.D, Sally Wenzel, M.D. Online Data Supplement METHODS
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationLung transplantation has become a feasible option. Bronchiolitis Obliterans Syndrome and Additional Costs of Lung Transplantation*
Bronchiolitis Obliterans Syndrome and Additional Costs of Lung Transplantation* Jan W. K. van den Berg, MD, PhD; Petra J. van Enckevort, PhD; Elisabeth M. TenVergert, PhD; Dirkje S. Postma, MD, PhD; Wim
More informationOriginal Contributions
Original Contributions Comparison of a New Desktop Spirometer (Spirospec) with a Laboratory Spirometer in a Respiratory Out-Patient Clinic François Swart, Macé M Schuurmans MD, Johannes C Heydenreich,
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationParametric response mapping
Parametric response mapping Utility of a novel imaging biomarker in pulmonary disease Dharshan Vummidi MD, Lama VN MD, Yanik G MD, Kazerooni EA MD, Meilan Han MD, Galban C PhD Radiology, Pulmonary & Critical
More informationThe role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE
The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE RHYS JEFFERIES ARTP education Learning Objectives Examine the clinical features of airways disease to distinguish
More informationTeacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology
Title: Spirometry Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology I. Measurements of Ventilation Spirometry A. Pulmonary Volumes 1. The tidal
More information4.6 Small airways disease
4.6 Small airways disease Author: Jean-Marc Fellrath 1. INTRODUCTION Small airways are defined as any non alveolated and noncartilaginous airway that has an internal diameter of 2 mm. Several observations
More informationLung Allograft Dysfunction
Lung Allograft Dysfunction Carlos S. Restrepo M.D. Ameya Baxi M.D. Department of Radiology University of Texas Health San Antonio Disclaimer: We do not have any conflict of interest or financial gain to
More informationChapter. Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension
Chapter 7 Diffusion capacity and BMPR2 mutations in pulmonary arterial hypertension P. Trip B. Girerd H.J. Bogaard F.S. de Man A. Boonstra G. Garcia M. Humbert D. Montani A. Vonk Noordegraaf Eur Respir
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationCOPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013
COPD, Asthma, Or Something In Between? Sharon R. Rosenberg Assistant Professor of Medicine Northwestern University December 4, 2013 None Disclosures Definitions Asthma Asthma is a chronic inflammatory
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationSpirometry. Obstruction. By Helen Grim M.S. RRT. loop will have concave appearance. Flows decreased consistent with degree of obstruction.
1 2 Spirometry By Helen Grim M.S. RRT 3 4 Obstruction loop will have concave appearance. Flows decreased consistent with degree of obstruction. Volumes may be normal, but can decrease with severity of
More informationImpact of the new ATS/ERS pulmonary function test interpretation guidelines
Respiratory Medicine (2007) 101, 2336 2342 Impact of the new ATS/ERS pulmonary function test interpretation guidelines Mary Elizabeth Kreider a,, Michael A. Grippi a,b a Division of Pulmonary, Allergy,
More informationThe case for extra fine particle ICS:! to cover the entire lung!
The case for extra fine particle ICS: to cover the entire lung Richard J. Martin, M.D. Chairman Department of Medicine National Jewish Health The Edelstein Chair in Pulmonary Medicine Professor of Medicine
More informationSpirometry: an essential clinical measurement
Shortness of breath THEME Spirometry: an essential clinical measurement BACKGROUND Respiratory disease is common and amenable to early detection and management in the primary care setting. Spirometric
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationDéjà vu all over again
Disclosures Déjà vu all over again None Jonathan Singer MD MS University of California, San Francisco HPI 49 y/o woman presents for lung transplant evaluation for Hypersensitivity Pneumonitis Exposures:
More informationCIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT
Circular Instruction 195 CIRCULAR INSTRUCTION REGARDING ESTABLISHMENT OF IMPAIRMENT DUE TO OCCUPATIONAL LUNG DISEASE FOR THE PURPOSES OF AWARDING PERMANENT DISABLEMENT COMPENSATION FOR OCCUPATIONAL INJURIES
More informationGeert M. Verleden, MD, PhD, FERS. Medical Director Leuven Lung Transplant Program
Geert M. Verleden, MD, PhD, FERS Medical Director Leuven Lung Transplant Program History of BOS A working formulation for the standardization of nomenclature and for clinical staging of Chronic C Dysfunction
More informationCOPD or not COPD, that is the question.
COPD or not COPD, that is the question. Asthma-COPD Overlap Syndrome: ACOS Do we really need this? Michelle Harkins Disclosure Slide Slide help - William Busse, MD Organizational Interests ATS, ACCP, ACP
More informationRESPIRATORY PHYSIOLOGY Pre-Lab Guide
RESPIRATORY PHYSIOLOGY Pre-Lab Guide NOTE: A very useful Study Guide! This Pre-lab guide takes you through the important concepts that where discussed in the lab videos. There will be some conceptual questions
More informationSpirometry: FEVER DISEASE DIABETES HOW RELIABLE IS THIS? 9/2/2010 BUT WHAT WE PRACTICE: Spirometers are objective tools
SPIROMETRY PRINCIPLES, PROCEDURE AND QA Spirometry: Dr. Rahul Kodgule CHEST RESEARCH FOUNDATION, PUNE FEVER ISCHAEMIC HEART DISEASE DIABETES BUT WHAT WE PRACTICE: Spirometers are objective tools to diagnose
More informationRespiratory Disease. Dr Amal Damrah consultant Neonatologist and Paediatrician
Respiratory Disease Dr Amal Damrah consultant Neonatologist and Paediatrician Signs and Symptoms of Respiratory Diseases Cardinal Symptoms Cough Sputum Hemoptysis Dyspnea Wheezes Chest pain Signs and Symptoms
More informationAnnual lung function changes in young patients with chronic lung disease
Eur Respir J 22; 19: 886 891 DOI:.1183/931936.2.2492 Printed in UK all rights reserved Copyright #ERS Journals Ltd 22 European Respiratory Journal ISSN 93-1936 Annual lung function changes in young patients
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationClinical and inflammatory determinants of bronchial hyperresponsiveness in COPD
Eur Respir J 212; : 19 115 DOI: 1.113/931936.169711 CopyrightßERS 212 Clinical and inflammatory determinants of bronchial hyperresponsiveness in COPD Maarten van den Berge*,#, Judith M. Vonk #,", Margot
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationEVect of breathing circuit resistance on the measurement of ventilatory function
9 Department of Respiratory Medicine, The Alfred Hospital and Monash University Medical School, Melbourne, Victoria, Australia 311 D P Johns C M Ingram S Khov P D Rochford E H Walters Correspondence to:
More informationPulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
More informationPREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION
Prediction Equations for Lung Function in Healthy, Non-smoking Malaysian Population PREDICTION EQUATIONS FOR LUNG FUNCTION IN HEALTHY, LIFE TIME NEVER-SMOKING MALAYSIAN POPULATION Justin Gnanou, Brinnell
More informationFrequency of nocturnal symptoms in asthmatic children attending a hospital out-patient clinic
Eur Respir J, 1995, 8, 2076 2080 DOI: 10.1183/09031936.95.08122076 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1995 European Respiratory Journal ISSN 0903-1936 Frequency of nocturnal
More informationIs there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions?
Respiratory Medicine (2004) 98, 178 183 Is there any correlation between the ATS, BTS, ERS and GOLD COPD s severity scales and the frequency of hospital admissions? Maria Tsoumakidou, Nikolaos Tzanakis,
More informationThe Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI
The Aging Lung Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI Is the respiratory system of the elderly different when compared to younger age groups? Respiratory Changes
More informationS P I R O M E T R Y. Objectives. Objectives 2/5/2019
S P I R O M E T R Y Dewey Hahlbohm, PA-C, AE-C Objectives To understand the uses and importance of spirometry testing To perform spirometry testing including reversibility testing To identify normal and
More informationPeak Expiratory Flow Is Not a Quality Indicator for Spirometry*
Original Research PULMONARY FUNCTION TESTING Peak Expiratory Flow Is Not a Quality Indicator for Spirometry* Peak Expiratory Flow Variability and FEV 1 Are Poorly Correlated in an Elderly Population Matthew
More informationSurvival impact of lung transplantation for COPD
Eur Respir J 2010; 36: 74 80 DOI: 10.1183/09031936.00087809 CopyrightßERS 2010 Survival impact of lung transplantation for COPD S. Lahzami*, P.O. Bridevaux #, P.M. Soccal #,", J. Wellinger +, J.H. Robert
More informationASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss?
ASTHMA-COPD OVERLAP SYNDROME 2018: What s All the Fuss? Randall W. Brown, MD MPH AE-C Association of Asthma Educators Annual Conference July 20, 2018 Phoenix, Arizona FACULTY/DISCLOSURES Randall Brown,
More informationDiagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma
ORIGINAL RESEARCH Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma Daphne C Richter 1 James R Joubert 1 Haylene Nell
More informationAssessment of Bronchodilator Response in Various Spirometric Patterns
Original Article 2013 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran ISSN: 1735-0344 TANAFFOS Assessment of Bronchodilator Response in Various Spirometric Patterns Amir Houshang
More informationVentilatory functions response to breathing training versus aerobic training in asthmatic children
Egypt J Pediatr Allergy Immunol 2012;10(1):33-37. Original article Ventilatory functions response to breathing training versus aerobic training in asthmatic children Background: There is worldwide public
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationAbnormalities of plethysmographic lung volumes in asthmatic children
Respiratory Medicine (2010) 104, 966e971 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Abnormalities of plethysmographic lung volumes in asthmatic children Bruno Mahut
More informationbehaviour are out of scope of the present review.
explained about the test, a trial may be done before recording the results. The maneuver consists initially of normal tidal breathing. The subject then inhales to maximally fill the lungs. This is followed
More informationINTERNET-BASED HOME MONITORING OF PULMONARY FUNCTION AFTER LUNG TRANSPLANTATION. 2000, 25 patients underwent heart lung (HLT) or bilateral-lung (BLT)
Online Supplement for: INTERNET-BASED HOME MONITORING OF PULMONARY FUNCTION AFTER LUNG TRANSPLANTATION METHODS Patients Between the start of the study in June 1998 and the end of the study in September
More informationDOES SMOKING MARIJUANA INCREASE THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE?
DOES SMOKING MARIJUANA INCREASE THE RISK OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE Pubdate: Tue, 14 Apr 2009 Source: Canadian Medical Association Journal (Canada) Copyright: 2009 Canadian Medical Association
More informationCoexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis
Volumes: IRV inspiratory reserve volume Vt tidal volume ERV expiratory reserve volume RV residual volume Marcin Grabicki Department of Pulmonology, Allergology and Respiratory Oncology Poznań University
More informationImportance of slow vital capacity in the detection of airway obstruction*
Original Article Importance of slow vital capacity in the detection of airway * Importância da capacidade vital lenta na detecção de obstrução das vias aéreas Ana Raquel Gonçalves de Barros, Margarida
More informationCitation for published version (APA): Ouwens, J. P. (2002). The Groningen lung transplant program: 10 years of experience Groningen: s.n.
University of Groningen The Groningen lung transplant program Ouwens, Jan Paul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationThe interaction of ageing and lung disease
Review Series: Old Age The interaction of ageing and lung disease Chronic Respiratory Disease 9(1) 63 67 ª The Author(s) 2012 Reprints and permission: sagepub.co.uk/journalspermissions.nav DOI: 10.1177/1479972311433766
More informationValidity of Spirometry for Diagnosis of Cough Variant Asthma
http:// ijp.mums.ac.ir Original Article (Pages: 6431-6438) Validity of Spirometry for Diagnosis of Cough Variant Asthma Iman Vafaei 1, *Nemat Bilan 2,3, Masoumeh Ghasempour 41 1 Resident of Pediatrics,
More informationPulmonary Function Testing
In the Clinic Pulmonary Function Testing Hawa Edriss MD, Gilbert Berdine MD The term PFT encompasses three different measures of lung function: spirometry, lung volumes, and diffusion capacity. In this
More informationDependence of forced vital capacity manoeuvre on time course of preceding inspiration in patients with restrictive lung disease
Eur Respir J 1997; 1: 2366 237 DOI: 1.1183/931936.97.112366 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1997 European Respiratory Journal ISSN 93-1936 Dependence of forced vital capacity
More informationInternational Journal of Health Sciences and Research ISSN:
International Journal of Health Sciences and Research www.ijhsr.org ISSN: 2249-9571 Original Research Article The Effect of Body Mass Index on Dynamic Lung Volumes Shinde PU 1, Irani FB 2, Heena Kauser
More informationInt. J. Pharm. Sci. Rev. Res., 34(2), September October 2015; Article No. 24, Pages: Role of Spirometry in Diagnosis of Respiratory Diseases
Review Article Role of Spirometry in Diagnosis of Respiratory Diseases Dipti Mohapatra 1, Tapaswini Mishra 1, Manasi Behera 1, Nibedita Priyadarsini 1, Arati Mohanty 1, *Prakash Kumar Sasmal 2 1 Department
More informationLife-long asthma and its relationship to COPD. Stephen T Holgate School of Medicine University of Southampton
Life-long asthma and its relationship to COPD Stephen T Holgate School of Medicine University of Southampton Definitions COPD is a preventable and treatable disease with some significant extrapulmonary
More informationCOPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases
COPD: early detection, screening and case-finding: what is the evidence? Prof. Jan-Willem Lammers, Md PhD Department of Respiratory Diseases «If you test one smoker with cough every day You will diagnose
More informationL ong term survival after lung transplantation is limited by
799 LUNG TRANSPLANTATION Bronchiolitis obliterans following lung transplantation: early detection using computed tomographic scanning P A de Jong, J D Dodd, H O Coxson, C Storness-Bliss, P D Paré, J R
More informationCitation for published version (APA): Ouwens, J. P. (2002). The Groningen lung transplant program: 10 years of experience Groningen: s.n.
University of Groningen The Groningen lung transplant program Ouwens, Jan Paul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationCitation for published version (APA): Ouwens, J. P. (2002). The Groningen lung transplant program: 10 years of experience Groningen: s.n.
University of Groningen The Groningen lung transplant program Ouwens, Jan Paul IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check
More informationContent Indica c tion Lung v olumes e & Lung Indica c tions i n c paci c ties
Spirometry Content Indication Indications in occupational medicine Contraindications Confounding factors Complications Type of spirometer Lung volumes & Lung capacities Spirometric values Hygiene &
More informationCOPD. Breathing Made Easier
COPD Breathing Made Easier Catherine E. Cooke, PharmD, BCPS, PAHM Independent Consultant, PosiHleath Clinical Associate Professor, University of Maryland School of Pharmacy This program has been brought
More informationS P I R O M E T R Y. Objectives. Objectives 3/12/2018
S P I R O M E T R Y Dewey Hahlbohm, PA-C, AE-C Objectives To understand the uses and importance of spirometry testing To perform spirometry testing including reversibility testing To identify normal and
More informationSPIROMETRY TECHNIQUE. Jim Reid New Zealand
Jim Reid New Zealand The Basics Jim Reid Spirometry measures airflow and lung volumes, and is the preferred lung function test in COPD. By measuring reversibility of obstruction, it is also diagnostic
More informationMaximal expiratory flow rates (MEFR) measured. Maximal Inspiratory Flow Rates in Patients With COPD*
Maximal Inspiratory Flow Rates in Patients With COPD* Dan Stănescu, MD, PhD; Claude Veriter, MA; and Karel P. Van de Woestijne, MD, PhD Objectives: To assess the relevance of maximal inspiratory flow rates
More informationPULMONARY FUNCTION TESTS
Chapter 4 PULMONARY FUNCTION TESTS M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University. OBJECTIVES Review basic pulmonary anatomy and physiology. Understand the reasons
More informationLung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits
More informationA Primer on Reading Pulmonary Function Tests. Joshua Benditt, M.D.
A Primer on Reading Pulmonary Function Tests Joshua Benditt, M.D. What Are Pulmonary Function Tests Used For? Pulmonary function testing provides a method for objectively assessing the function of the
More informationThe FDA Critical Path Initiative
The FDA Critical Path Initiative Clinical Considerations for Demonstration of Dose-response for Inhaled Corticosteroids - Exhaled Nitric Oxide Model Badrul A. Chowdhury, MD, PhD Director Division of Pulmonary
More informationValue of measuring diurnal peak flow variability in the recognition of asthma: a study in general practice
Eur Respir J ; : DOI:./.. Printed in UK - all rights reserved Copyright ERS Journals Ltd European Respiratory Journal ISSN - Value of measuring diurnal peak flow variability in the recognition of asthma:
More informationAsthma COPD Overlap (ACO)
Asthma COPD Overlap (ACO) Dr Thomas Brown Consultant Respiratory Physician Thomas.Brown@porthosp.nhs.uk Dr Hitasha Rupani Consultant Respiratory Physician Hitasha.rupani@porthosp.nhs.uk What is Asthma
More informationKey words: bronchodilation; diffusing capacity; high-resolution CT; lung volumes; spirometry
Assessment of Emphysema in COPD* A Functional and Radiologic Study Isa Cerveri, MD; Roberto Dore, MD; Angelo Corsico, MD, PhD; Maria C. Zoia, MD; Riccardo Pellegrino, MD; Vito Brusasco, MD; and Ernesto
More informationBasic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic
Basic approach to PFT interpretation Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic Disclosures Received honorarium from Astra Zeneca for education presentations Tasked Asked
More informationRelationship Between FEV1& PEF in Patients with Obstructive Airway Diseases
OBSTRUCTIVE THE IRAQI POSTGRADUATE AIRWAY MEDICAL DISEASES JOURNAL Relationship Between FEV1& PEF in Patients with Obstructive Airway Diseases Muhammed.W.AL.Obaidy *, Kassim Mhamed Sultan*,Basil Fawzi
More informationUsing Spirometry to Rule Out Restriction in Patients with Concomitant Low Forced Vital Capacity and Obstructive Pattern
44 The Open Respiratory Medicine Journal, 2011, 5, 44-50 Using Spirometry to Rule Out Restriction in Patients with Concomitant Low Forced Vital Capacity and Obstructive Pattern Open Access Imran Khalid
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationComparison of Frequency of FEV1 in Asymptomatic Smoker and Nonsmoker Doctors
Journal of US-China Medical Science 13 (2016) 58-63 doi: 10.17265/1548-6648/2016.02.002 D DAVID PUBLISHING Comparison of Frequency of FEV1 in Asymptomatic Smoker and Nonsmoker Doctors Asim Shaukat, Hassan
More informationStudy of pulmonary functions in Yoga performing group and non-yogics
8 Study of pulmonary functions in Yoga performing group and non-yogics Dr. Nilay A. Kapadia*, Dr. Ashok Goswami**, Dr. Prakash Chaudhari*, Dr. Kalpan Desai*Dr Janardan V Bhatt @ *P.G.Student, Department
More informationRespiratory System Mechanics
M56_MARI0000_00_SE_EX07.qxd 8/22/11 3:02 PM Page 389 7 E X E R C I S E Respiratory System Mechanics Advance Preparation/Comments 1. Demonstrate the mechanics of the lungs during respiration if a bell jar
More informationUnderstanding the Basics of Spirometry It s not just about yelling blow
Understanding the Basics of Spirometry It s not just about yelling blow Carl D. Mottram, RRT RPFT FAARC Technical Director - Pulmonary Function Labs and Rehabilitation Associate Professor of Medicine -
More informationPrevalence of undetected persistent airflow obstruction in male smokers years old
2 Prevalence of undetected persistent airflow obstruction in male smokers 40-65 years old Geijer RMM Sachs APE Hoes AW Salomé PL Lammers J-WJ Verheij TJM Published in: Family Practice 2005;22:485-489 Abstract
More informationThe Relationship Between FEV 1 and Peak Expiratory Flow in Patients With Airways Obstruction Is Poor*
Original Research PULMONARY FUNCTION TESTING The Relationship Between FEV 1 and Peak Expiratory Flow in Patients With Airways Obstruction Is Poor* Ashutosh N. Aggarwal, MD, FCCP; Dheeraj Gupta, MD, FCCP;
More informationTo assess the pulmonary impairment in treated pulmonary tuberculosis patients using spirometry
Original Research Article To assess the pulmonary impairment in treated pulmonary tuberculosis patients using spirometry Dhipu Mathew 1, Kirthana G 2, Krishnapriya R 1, Srinivasan R 3 1 Assistant Professor,
More informationPDF hosted at the Radboud Repository of the Radboud University Nijmegen
PDF hosted at the Radboud Repository of the Radboud University Nijmegen The following full text is a publisher's version. For additional information about this publication click this link. http://hdl.handle.net/2066/21235
More informationAPSR RESPIRATORY UPDATES
APSR RESPIRATORY UPDATES Volume 4, Issue 7 Newsletter Date: July 2012 APSR EDUCATION PUBLICATION Inside this issue: Quantitative imaging of airways Small-Airway Obstruction and Emphysema in Chronic Obstructive
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationAssessment of accuracy and applicability of a new electronic peak flow meter and asthma monitor
Eur Respir J 18; 12: 45 42 DOI: 18/1.8.5 Printed in UK - all rights reserved Copyright ERS Journals Ltd 18 European Respiratory Journal ISSN - 1 Assessment of accuracy and applicability of a new electronic
More informationExhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma
Exhaled Nitric Oxide: An Adjunctive Tool in the Diagnosis and Management of Asthma Jason Debley, MD, MPH Assistant Professor, Pediatrics Division of Pulmonary Medicine University of Washington School of
More informationEfficacy of a Heat Exchanger Mask in Cold Exercise-Induced Asthma* David A. Beuther, MD; and Richard J. Martin, MD, FCCP
Original Research ASTHMA Efficacy of a Heat Exchanger Mask in Cold Exercise-Induced Asthma* David A. Beuther, MD; and Richard J. Martin, MD, FCCP Study objectives: To determine the efficacy of a novel
More informationPeak expiratory flow and the resistance of the mini-wright peak flow meter
Eur Respir J, 1996, 9, 828 833 DOI: 10.1183/09031936.96.090828 Printed in UK - all rights reserved Copyright ERS Journals Ltd 1996 European Respiratory Journal ISSN 0903-1936 TECHNICAL NOTE Peak expiratory
More information